Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Notably, linagliptins ability to block this interaction in an in vitro system lacking GLP-1 suggests an M6P-mediated approach independent of GLP-1 (unpublished data)
WR conceived and designed the study, interpreted the data, and wrote the manuscript
The FDA flagged theoretical immunogenicity risk in its Category 2 listing
Malabsorption (insufficient absorption of vitamin B12 in the intestine) due to insufficient production of intrinsic factor (a protein produced in the lining of the stomach that is needed to absorb vitamin B12), disorders in the end section of the ileum (part of the small intestine), such as sprue, fish tapeworm infestation or blind loop syndrome (change in the course of the intestine after gastric surgery)
